The co ncept of skin-associated lymphoid tissue embraces those cells and functions that are integrated in the cutaneous host defense. Recently, it has been possible to identify those circulating T -cells that are skin associated. These cells display the cell-surface phenotype of memory T cells (CD45RO+) and express the cutaneous lymphocyte antigen, a tissue-selective homing receptor involved in directing T-cell traffic to inflamed skin. To investigate the participation of this skinassociated T-cell subset in the pathogenesis of cutaneous Tcell lymphoma, we studied 16 patients with erythrodermic cutaneous T -cell lymphoma for the presence of these surface proteins on circulating cells. Results were compared with eight patients in remission and eight with minimal patchplaque cutaneous T -cell lymphoma. The m ean expression of T he distribution of the immune repertoire and the functional coordination of spatially distinct compartments of the immune system is critically dependent on a closely regulated system oflymphocyte homing. This system directs naive T lymphocytes to the organized lym phoid microenvironment of secondary lymphoid tissues, such as lymph nodes or Peyer's patches, in which they can be specifically ac tivated by thei r specific foreign antigen in conjunction with appropriate accessory cells. N aive T cells (CD45RA +RO-) [1-5] extravasate poorly, if at all, in extralymphoid ("tertiary") sites. In contrast, memory/effector T cells (CD45RO+) ge nerated in secondary lymphoid tissues in response to stimu lation by antigen migrate efficiently to such sites, where they "patrol" for the return of their particular antigen. Memory/effector T cells do not, however, home equivalently to all possible tissues; instead they demonstrate tissue-selective homing to particular secondary and tertiary sites (reviewed in [1 D.
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both CD45RO and cutaneous lymphocyte antigen were significantly greater in the erythrodermic patients than in the other two patient groups. Expression of these markers was shown to be on the cells of the m alignant clone by two-color flow cytometry. These results demonstrate that the malignant cells of cutaneous T -cell lymphoma express the markers of skin homing lymphocytes and that their levels are increased in the erythrodermic cutaneous T-cell lymphoma patients. Moreover, the findings suggest a critical role for the skin-selective homing receptor cutaneous lymphocyte antigen in the pathogenesis of cutaneous T -cell lymphoma. Key words: cutaneous T-cell lymphoma, cutaneous lymphocyte antigen, CD45 isoforms. ] itlllest D ermatol 101 :222 -226, 1993 ciated antigen (CLA) with endothelial cell E-selectin (formerly known as ELAM-l), which in the setting of chronic inflammation is preferentially induced on cutaneous venul es (i.e. , is a skin vascular "addressin") [6 -9] . CLA is expressed on the vast majority ofT cells within cutaneous inflammation sites, and on a subset of peripheral blood memory cells, but not on the great majority of T cells in extracutaneous sites [6, 7] . Cutaneous T -cell lymphoma (CTCL) is a disease characterized by cutaneous infiltrates of ma lignant c10nally expanded T cells admixed with an inflammatory infi ltrate. The disease typically begins with erythematous patches, which then progress to more infiltrated pl aques [10] . Dissemination of CTCL cells can occur hematogenously. When this occurs, the clinical picture of erythroderma may appear. The malignant cells in CTCL are a c10nally expanded T-cell subpopulation that contain the same T-cell receptor (TCR) ge ne rearrangements [11] .
Recombination of genes encoding th e variable regions of the chain of the T-cell receptor (TCR) contribute greatly to the generation of diversity in the TCR [1 2]. The number of different variable regions for the human chain is probably greater than 40 but the precise number is not known [13] . Monoclonal antibodies with specificity for a small number of these are already available, defilLing fami lies of TCRs (as shown in T able I) . No single one of these identifiable variable regions is expressed on more than 5% of circulating T cells in normal individuals , and most are expressed on less than 3%. The validity of th e use of a particular family-specific antibody to identify the malignant clone was confirmed by us in an RNAse protection assay, demonstrating CTCL cell production of message for these same variable regions [13] . Thus, it is possible to clearly identify malignant cells in select patients with antibodies directed against the variable region sequences for the beta chain [14] . CLA has been demonstrated to be present on the surface of skininfiltrating lymphocytes in all patients studied with patch-plaque CTCL, but not non-skin-associated T-cell lymphomas [6J, suggesting the possibility that the CLA:E-selectin interaction plays a role in the epidermotropic nature of this unique neoplasm. To investigate this hypothesis, we sought to quantify T cells of the skin homing phenotype in the peripheral blood of patients with erythrodermic CTCL, patients with minimal patch/plaque CTCL, and patients with CTCL in remission. Our results indicated that patients with erythrodermic CTCL have increased circulating lymphocytes bearing both CLA and CD45RO. Two of the patients in this study had malignant clones detectable by one of the panel of variable region antibodies. In those patients it can be clearly demonstrated that the circulatin g CLA + and CD45RO+ cell s were malignant cells on th e basis of co-expression with the family-specific antibody.
MATERIALS AND METHODS
Patients A total of 16 patients with erythrodermic CTCL were evaluated in conj uncti on with their visits to the Dermatology Clinic at Yale University. All had a skin biopsy diagnostic of CTCL (morphologically atypica l cells in dermal infil trates and in the epidermis, with Pautrier abscess formation) in conjunction with erythroderma. Eight patients with patch-plaque disease « 10% body surface area) of CTCL were studied, as were eight patients in remission from erythrodermic CTCL at the time of study.
Preparation of Peripheral Blood Mononuclear Cells
Patients' blood samples were collected in tubes containing heparin. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation as follows. Whole blood was diluted with Hank's balanced salt solution (HBSS) (GIBCO) ata ratio of3: 1. The diluted blood was layered over Ficoll Histopaque-l077 (Sigma Diagnostics) and centrifu ged at 300 X g for 35 min at room temperature. The PBMC were harvested from the interface, resuspended, and washed two times in HBSS with 5% fetal calf serum (GIBCO).
Monoclonal Antibodies Patients' PBMC were incubated with a variety of monoclonal antibodies. The anti-CD4SRO (UCHLl) was directly conjugated with fluorescein isothiocynate (FITC) (Dakopatts, Denmark). The unconj ugated murine monoclonal antibodies listed in Table I were purchased from T-cell Sciences, Cambridge. The antibody to CLA was directly conjugated with FITC and this was prepared as previously described [6,7J. Mouse ascites fluid was prepared and utilized as previously described [1 5 ] to control for non-specific binding of murine antibody in both one-color and two-co lor stndies. The seco ndary antibody, FITC-conjugated goat antimouse IgG, was purchased from The Binding Site, San Diego.
Immunofluorescence Isolated PBMC were incubated with primary monoclonal antibody at a concentration of 100,000/10 J.Ll cells for 30 min at 4 ° C. The primary monoclonal antibodies were used at concentrations of 0.2 Ilg/I0 Ill. After the incubation period, the cel ls were resuspended and washed two times by centrifugation at 200 X g (4°C) for 5 min with 500 pI PBS (pH 7.4) con taining 10% human serum, type AB (GJBCO) and 0.1 % sodium azide. FITC-conjugated goat anti-mouse was added to the cells at a concentration of 5 Ilg/I0 III with 10 pl/l00,OOO cells used in incubation for 30 min at 4°C. After the secolJdary staining, the PBMC were washed as stated above.
For two-color immunofluorescent studies, isolated PMBL were initially stained with a monoclonal antibody to the T-cell receptor variable region (either VBS[a] or VB8[a]), which was diluted as described above. The cells were incubated, washed, and resuspended as described in the previous section. The secondary antibody, biotinylated goat anti-mouse IgG, was purchased from Vector Laboratories and the stock solution was diluted 1: 200 with PBS. After incubation with the biotinylated antibody, the cells were HOMING MECHANISMS IN CTCL 223 resuspended and was hed two times by centrifu gation at 200 X g (4°C) for 5 min with 500 Ill/PBS (pH 7.4) containing 10% human serum, type AB (GIBCO) and 0.1 % sodium azide. Following the last washing step, the cells were stained with phycoerythrin-conjugated avidin (PE-A) (CALTAG, Laboratories), whic h was diluted with PBS to a concentration of 1: 10. After a 3D-min incubation, cells were washed twice as described above and then incubated with the FITC-co~ugated monoclonal antibody to CD45RO or CLA.
Flow Cytometry Analysis For flow cytometry ana lysis, the cells were resuspended in a final vo lume of 500 III PBS. A cytofluorograph IIa (Ortho Diagnostics Systems Inc, Westwood, MA) with an Argon laser (Exel , Westwood, MA) was used for fluorescence analysis. Gating was performed on lymphocytes and background fluorescence was set at 5%. The percentages of positive cells were obtained by subtracting 5% from the percent expressin g cells. For two-color flow cytometry, red and green background fluorescence was set at 5%. The two-color flow cytograms were divided into four quadrants based on each line being drawn at 5% co ntrol immunofluorescence. The percentage of cells in each quadrant is displayed on the cytogram. Results were thus expressed as a percentage of total lymphocytes. Twocolor flow cytometry was performed on a Dual Laser FACS IV (Becton Dickinson).
Statistical Analysis The correlation coefficient (r) was used to measure the strength of the linear association between the flow cytometric results with CD4SRO and CLA. Student t test was used to test for differences between the study groups: p < 0.05 was considered significant.
RESULTS

CD45RO Expression
The results of memory cell analysis on PBMCs from CTCL patients in remission and those w ith limited cutaneous disease were similar to those reported for normal controls [4] . In the 16 non-leukemic patients, CD45RO was expressed on a mean of 15% of total lymp hocytes in the eight in remission, and a mean of 13.5% of total lymphocytes in the eight patients with patch-plaque disease. None of the patients in remission or with limited patch-plaque disease had greater than 33% of peripheral blood lymphocytes expressing CD45RO , whereas most of the leukemic patients were above this level, as shown in Fig 1. In the leukemic CTCL group CD45RO expression was markedly elevated, with a mean of 56% of total lymphocytes, which was significantly higher than that seen in the non-leukemic patients (p < 0.05) . Table I , only two patients were identified with elevated levels of circulating cells expressing a particu lar VB. Normally , less than 5% of circulating cells express a given VB. One patient had circulating cells expressing 77% VB8; 4 weeks later this patient had 84% VB8(a) expressing cells. The second patIent had 93% VB5(a) expressin g cells. Twocolor flow cytometry demonstrated that CD45RO is expressed on the malignant clone. In Fig 2, the percentage of CD45RO+VB8+ cells in that patient was 67% whereas only 4% were CD45RO+VB8-and 11 % were CD45RO-VB8+.
Coexpression of CD45RO and TCR VB Epitopes Of all 16 leukemic patients screened with the panel of the variable region of the beta chain of the T-cell receptor (VB) antibodies in
CLA Expression The results of CLA expression ana lys is o n
PBMCs from CTCL patients in remission and those with limited cutaneous disease were similar to those reported for normal controls [6] . The percentage of lymphocytes bearing CLA in the 16 non-leukemic patients showed a mean of 15.5 for the eight in remission, and a mean of 14.5 for the eight patients with patch-plaque disease. None of the limited patch-plaque disease patients or those in remission had greater than 21 % of peripheral blood lymphocytes expressing CLA, as shown in Fig 3. In contrast, in the leukemic CTCL group, CLA expression was significantly elevated, being expressed on a mean of 52% of peripheral blood lymphocytes (p < 0.01 compared to non-leukemic patients). In addition, 14 of the 16 patients had > 21 % of peripheral blood lymp hocytes expressing CLA.
Coexpression of CLA and TCR VB Epitopes In the resu lts presented above it was reported that VB antibody screening of peripheral blood lymp hocytes found that one patient's peripheral blood lymphocytes expressed the epitope recognized by VB5(a) and one recognized by VB8(a). Two-color flow cytometry with the VB antibodies demonstrated that CLA is expressed on the malignant clone (Fig 4A,B) . The patient sample shown in Fig 4A was the same patient as in Fig 2 at a later date, when 84% of the peripheral blood lymphocytes were expressing VB8. In Fig 4A, 52% of the circulating lymphocytes were CLA+VB8+; however, 32% of the lymphocytes expressed VB8 but did not express CLA. The patient sample in Fig 4B was characterized by having 93% of the lymphocytes expressing the VB epitope recognized by antibody VB5(a). As shown in Fig 4B, a large number of clonally expanded VB5(a)+ cells are CLA + (52%). As with the patient sample in Fig 4A, there were VB+ and CLA -peripheral blood lymphocytes (41 %).
Correlation of CD45RO and CLA In Fig 5, each patient analyzed is represented by a single point whose position was plotted as a dual function of the percentage of CD45RO+ lymphocytes (y-axis) and the percentage of CLA + lymphocytes (x-axis). As can be seen in 
DISCUSSION
The concept that the skin constitutes a specific immunologic microenvironment is not a new one [16, 17] , but has received a great deal of support in recent years from studies indicating that unique constituents of the skin such as Langerhan's cells, keratinocytes, and melanocytes can extensively interact with lymphocytes, either by secretion of immunoreactive cytokines or by expression of cell adhesion/recognition receptors (e.g., ICAM-1, HLA-DR) that mediate direct cell-cell contact [18] . Moreover, it is now clear that the lymphocytes entering the skin are themselves a unique subpopulation, and that the skin represents a distinct lymphocyte homing specificity [6, 7] . Skin-associated lymphocytes are primarily T cells that display the CD45RO+ phenotype of memory T cells [19] , and selectively express the cell-surface determinant CLA [6] . CLA is an oligosaccharide ligand for E-selectin, a vascular adhesion molecule that in the setting of chronic inflammation is preferentially expressed in skin, and it is thought that the CLA: E-selectin interaction is a major determinant of the skin-selective T-cell homing specificity [1 ,6-9] . The clinical syndromes made up of certain T ce ll malignancies localizing to the skin have been collectively known as CTCL [10, 20, 21] . The existence of these skin homing lymphomas has long been used as an argument for a skin-selective homing specificity in man. Now, with the recognition that there is a physiologic, skin-associated T-cell subset, it has become possible to address this issue from the reverse perspective, that of defining the cellular and molecular mechanisms underlying the distinct pathophysiology of these neoplasms. In this report, we demonstrate that patients with erythrodermic CTCL have in their peripheral blood elevated levels of cells expressing the memory marker CD45RO and the skin homing receptor CLA. Moreover, in patients whose malignant clone could be unequivocally identified with monoclonal antibodies against T-cell receptor variable region'epitopes, the predominant phenotype of the malignant population was CD45RO+, CLA+. These results are in keeping with a previous study demonstrating the CTCL leukemic cells preferentially home to skin [22] . and are consistent with studies showing that the malignant skin infiltrates of patch/plaque-stage mycosis fungoides have a memory T-cell phenotype [23] , and are predominantly CLA+ [6] . As CLA expression is not a feature ofT-cell lymphomas in extracutaneous sites [6] , these observations suggest that the variants of CTCL that have appeared under the colorful names of mycosis fungoides, Pagetoid reticulosis, Sezary syndrome, etc. can now be unified by the concept that they are malignancies of cutaneous T cells (skin homing memory T cells). The studies of CLA expression also suggest that the same mechanisms directing the normal skin-selective homing of this subset may underlie the distinctive skin localization of these neoplasms.
Recent advances in the understanding of the normal regulation of CD45 isoforms and CLA in physiologic situations suggest provocative hypotheses on the origins and pathogenesis of CTCL. Virgin T cells emigrating from the thymus or recirculating among secondary lymphoid tissues have a CD45RA+/CLA-phenotype. Activation of these virgin T cells in secondary lymphoid tissues leads to the replacement of CD45RA by the RO isoform, and, depending on the local microenvironment, upregulation of CLA (CLA upregulation is over five times more frequent in peripheral lymph nodes draining skin than in non-skin-associated secondary lymphoid tissues such as the appendix [24, 25) ). Cutaneous T cells obtained from suction blisters overlying delayed hypersensitivity reactions are almost entirely CD45RO+ [19] ' and CLA + (the mean CLA expression of cutaneous T cells is 23 times higher than that of peripheral blood T cells [25] . Because malignant transformation likely occurs or becomes manifest in a proliferating cell, the finding that CTCL cells are CD45RO+/CLA+ suggests that malignant T-cell clones of CTCL arise either in T cells undergoing the virgin-to-memory transition in secondary lymphoid tissues (most likely peripheral lymph node) or in CLA+ memory T cells activated in the skin. Thus, it is likely that at the time of transformation, CTCL clones have "seen" antigen and undergone antigen-driven activation [26] . The microenvironment of this activation is presumably favorable to the upregulation of the CLA epitope. Furthermore, it is possible that the maintenance of CLA expression on the malignant clone requires continued re-stimulation in an appropriate microenvironment. The finding that CTCL cells often express a T-cell receptormediated activation marker (BE2) is in keeping with this hypothesis [15, 27] .
A requirement for continuous CLA upregulation might explain the finding that not all circulating CTCL cells are CLA + (Fig 4) . The CLA+ and CLA-subsets might reflect cells recently exposed to the cutaneous or other appropriate microenvironment versus those not receiving such CLA-inducing signals. Another explanation for the VB+CLA -cells would be that these are tumor cell s in the process of dedifferentiation . Followup studies will determine if this is a sign of tumor progression. Clinical progression of CTCL is associated with loss of epidermotropism and widespread dissemination [10] . It is possible that loss of CLA expression with tumor dedifferentiation plays a role in this process. Such loss may occur directly, with loss of expression of the core polypeptide of CLA or the glycosyl transferases required to produce its unique oligosaccharide side chain, or may occur indirectly by virtue of the tumor losing the ability to respond to CLAinducing stimuli. Preliminary observations suggesting that development of (non-epidermotropic) tumor stage CTCL is associated with (and perhaps preceeded by) loss of CLA expression [6] support this hypothesis. Previous studies have suggested the potential utility of T-cell receptor variable region-specific antibodies in the diagnosis and monitoring of T-cell malignancies [14] ; the results of this study confirm this potential. Unfortunately, the current paucity of rea- ge nts prevents application of this technique to all patients with CTCL. As the ava il ab le panel of such reagents becomes more complete, or in those patients whose malignant cells happen to bind one of the currentl y avail able reagents, the use of multiparameter fl ow cytometry to simultaneously assess the expression of the clone-specific T-cell receptor variable regions, CLA and CD45RO, will provide new insights into the pathophysiology of lymphomas of cutaneous T cells.
This study lIIas supported by NIH Gran ts SR01CA430S8-06 arId AI3154S-01 .
